| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| I646147-5mg |
5mg |
期货  |
| |
| I646147-10mg |
10mg |
期货 |
|
| 别名 | 约克西兰 |
|---|---|
| 英文别名 | A4YJ7J11TG | IOXILAN [JAN] | Ioxilane | UNII-A4YJ7J11TG | V08AB12 | IOXILAN [INN] | NSC 760056 | SR-01000883963-1 | Ioxilan(400 mg) | Imagenil | IOXILAN [USP-RS] | 1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N1-(2,3-DIHYDROXYPROPYL)-N3- |
| 规格或纯度 | ≥98% |
| 英文名称 | Ioxilan |
| 生化机理 | Ioxilan 是一种低渗透性、非离子和三碘诊断造影剂。伊奥昔兰也是一种 X 射线造影剂，可用于排泄性尿路造影以及头部和身体的造影增强计算机断层扫描（CECT）成像。血管内注射结果 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用机制 | 诊断剂 |
| 产品介绍 |
Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs . In Vitro As a low-osmolar nonionic monomer, Ioxilan increases the safety and tolerance of X-ray contrast agents. The development of Ioxilan is based on the introduction of a double methylene as a hydrophobic region and masking it with a hydrophilic hydroxyl group could lower the osmolality without adversely affecting the biological tolerance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Rapid intravenous injection of water-soluble X-ray contrast agents (Ioxilan) can be performed with dynamic computed tomography to improve the detectability of liver lesions. When injected intravenously, water-soluble, intravenous X-ray contrast agents are largely distributed in the extracellular fluid space and excreted unchanged by the kidneys. Contrast enhancement of a region of interest depends on the route of administration, delivery of the agent to the area by blood flow, and the final iodine concentration in the region . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
| 纯度 | ≥98% |
| ALogP | -2.4 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide |
| INCHI | 1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) |
| InChi Key | UUMLTINZBQPNGF-UHFFFAOYSA-N |
| Smiles | CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCCO)I |
| Isomeric SMILES | CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCCO)I |
| PubChem CID | 3743 |
| 分子量 | 791.11 |
| 溶解性 | DMSO : ≥ 250 mg/mL (316.01 mM) |
|---|---|
| 分子量 | 791.100 g/mol |
| XLogP3 | -2.400 |
| 氢键供体数Hydrogen Bond Donor Count | 7 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 11 |
| 精确质量Exact Mass | 790.87 Da |
| 单同位素质量Monoisotopic Mass | 790.87 Da |
| 拓扑极表面积Topological Polar Surface Area | 180.000 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 647.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 2 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
首页
400-620-6333
